Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CHS-1420 · 1 trial · 1 indication
The efficacy success criterion was the equivalence between CHS-1420 and Humira at Week 12. Equivalence was based upon 2-sided 95% confidence interval (CI) for the difference between the proportions of subjects in the CHS-1420 and Humira groups achieving PASI-75 at Week 12. If the 95% CI lay entirely within the interval (-15%, 15%), equivalence was established.
| Arm | Type | Description |
|---|---|---|
| Humira (adalimumab) | ACTIVE_COMPARATOR | Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end. |
| CHS-1420 | EXPERIMENTAL | CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end. |
| Name | Type | Description |
|---|---|---|
| CHS-1420 | DRUG | - |
| Adalimumab | DRUG | - |
Inclusion Criteria: * Male or female adults * PsO diagnosis for 6 months * Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale of 0-5), * Body Surface Area (BSA) involved with PsO greater than or equal to 1...
CHS-1420 is an investigational small molecule being developed for the treatment of plaque psoriasis. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with chronic plaque psoriasis.
CHS-1420 is being developed by Coherus Oncology, Inc., a company traded on the NASDAQ under the ticker symbol CHRS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with plaque psoriasis.
CHS-1420 is in Phase 3 clinical development. It is an investigational drug and has not yet received regulatory approval. A Phase 3 clinical trial comparing CHS-1420 to Humira in patients with chronic plaque psoriasis has been completed.
CHS-1420 has one completed Phase 3 clinical trial registered as NCT02489227. This randomized, double-blind, active-controlled study compared CHS-1420 to Humira in 545 subjects with chronic plaque psoriasis across multiple countries including the United States, Canada, and European nations.
CHS-1420 is a small molecule therapeutic. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not described here. It is being studied for its ability to treat plaque psoriasis.
No, CHS-1420 is not the same as Humira. CHS-1420 is an investigational small molecule, while Humira is a biologic. They were compared directly in a Phase 3 clinical trial to evaluate CHS-1420's efficacy and safety relative to Humira in patients with chronic plaque psoriasis.